Kalaris Therapeutics, Inc. KLRS 深 滬
已收盤 02-06 16:00:00 美东时间
8.34
-0.010
-0.12%
華盛通- 最 高8.75
- 今 開8.37
- 成交量 4.43万股
- 最 低 8.29
- 昨 收 8.35
- 總市值 1.56亿
- 52周最高 12.90
- 市盈率 靜 --
- 換手率 0.24%
- 52周最低 2.14
- 委 比 -86.03%
- 總股本 1870.24万
- 歷史最高 1126.08
- 量 比 1.15
- 振 幅 5.51%
- 歷史最低 7.915
- 每 手 1
- 風險率 2.75%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Kalaris Therapeutics To Present Clinical Data From Phase 1 Study Of TH103 At 49th Annual Meeting Of Macula Society
Kalaris Therapeutics, Inc. (NASDAQ:KLRS) ("Kalaris"), a clinical-stage biopharmaceutical company developing differentiated therapies for retinal diseases, today announced that clinical data from its Phase 1 study of
01-29 05:23
美股大行评级 | 潜在涨幅63.56%！拜玛林制药获Truist Securities升目标价至100美元，维持"买入"评级
今日重点评级关注：Truist Securities：维持拜玛林制药"买入"评级，目标价从80美元升至100美元；HC Wainwright & Co.：维持Savara"买入"评级，目标价从8美元升至10美元
2025-12-24 11:17
Kalaris Therapeutics Data From Phase 1a Single Dose Study Of TH103 Demonstrates Showed Mean 10-letter Gain In Visual Acuity, Rapid; TH103 Was Generally Well Tolerated
Kalaris Therapeutics, Inc. (NASDAQ:KLRS), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases, today announced positive initial data
2025-12-18 05:03
Kalaris Therapeutics Q3 EPS $(0.64) Beats $(0.65) Estimate
Kalaris Therapeutics (NASDAQ:KLRS) reported quarterly losses of $(0.64) per share which beat the analyst consensus estimate of $(0.65) by 1.99 percent. This is a 97.73 percent increase over losses of $(28.16) per share
2025-11-12 21:14
美股大行评级 | 高盛上调英伟达目标价升至240美元； Loop Capital上调英伟达目标价升至350美元！
今日重点评级关注：花旗：维持Caribou Biosciences"买入"评级，目标价从5美元升至8美元；HC Wainwright & Co.：上调MoonLake Immunotherapeutics - Class A Ordinary Shares评级至"买入"，目标价30美元
2025-11-04 10:31
Kalaris Therapeutics Appoints Matthew Gall As New CFO To Support Growth And Clinical Expansion
Kalaris Therapeutics ("Kalaris"), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases, today announced the appointment of Matthew
2025-11-03 20:38
Kalaris to Present at Stifel 2025 Annual Healthcare Conference
Kalaris Therapeutics announced that its management, including CEO Andrew Oxtoby and CMO Matthew Feinsod, will present at the Stifel 2025 Annual Healthcare Conference on November 13, 2025, from 3:20 – 3:50pm ET at the Lotte New York Palace Hotel. The company, focused on developing treatments for retinal diseases like nAMD, DME, and RVO, will also offer one-on-one meetings for interested parties during the event.
2025-10-30 12:00
Kalaris Therapeutics Now Enrolling Phase 1b/2 Multiple Ascending Dose Study of TH103 in Neovascular Age-Related Macular Degeneration
Kalaris Therapeutics has initiated a Phase 1b/2 multiple ascending dose (MAD) study for TH103 in patients with neovascular age-related macular degeneration (nAMD). The study, enrolling up to 80 patients, aims to evaluate the safety and preliminary efficacy of monthly intravitreal injections, with initial data expected in late 2026. TH103, a novel anti-VEGF therapy, is designed to provide increased and longer-lasting activity. The Phase 1a single ...
2025-09-15 12:00
美股大行评级 | 潜在涨幅403.28%！瑞杰金融首予Kalaris Therapeutics"强烈买入"评级，目标价23美元
今日重点评级关注：花旗：维持Ionis Pharmaceuticals"买入"评级，目标价从69美元升至84美元；Melius Research：上调康明斯评级至"买入"，目标价500美元
2025-09-04 09:49
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Biodesix (NASDAQ:BDSX) shares increased by 21.6% to $0.52 during Wedne...
2025-09-04 05:06
